Xianyang Wang Selected Research

ruzinurad

1/2022

Safety and efficacy of SHR4640 combined with febuxostat for primary hyperuricemia: a multicenter, randomized, double-blind, phase II study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Xianyang Wang Research Topics

Disease

4	Infections 04/2024 - 01/2023
4	Neoplasms (Cancer) 12/2022 - 07/2015
2	Communicable Diseases (Infectious Diseases) 12/2022 - 07/2015
2	Osteosarcoma (Osteogenic Sarcoma) 01/2017 - 07/2015
1	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2023
1	Virus Diseases (Viral Diseases) 01/2023
1	Dengue (Dengue Fever) 01/2022
1	Gout 01/2022
1	Inflammation (Inflammations) 01/2022
1	Gouty Arthritis 01/2022
1	Hyperuricemia 01/2022

Drug/Important Bio-Agent (IBA)

2	Uric Acid (Urate)IBA 01/2022 - 01/2022
2	polyphyllin IIBA 01/2017 - 07/2015
1	benzimidazoleIBA 04/2024
1	Antiviral Agents (Antivirals)IBA 03/2024
1	polycarpineIBA 03/2024
1	AntigensIBA 01/2023
1	VaccinesIBA 01/2023
1	Proteins (Proteins, Gene)FDA Link 01/2023
1	2-bromopalmitateIBA 01/2023
1	GlycoconjugatesIBA 01/2023
1	Polysaccharides (Glycans)IBA 01/2023
1	RNA (Ribonucleic Acid)IBA 01/2023
1	TransferasesIBA 01/2023
1	CytokinesIBA 01/2022
1	purineIBA 01/2022
1	ginsenoside M1IBA 01/2022
1	Febuxostat FDA Link 01/2022
1	Complement System Proteins (Complement)IBA 01/2022
1	ruzinuradIBA 01/2022
1	Cytokine Receptors (Cytokine Receptor)IBA 01/2022
1	GinsenosidesIBA 01/2022
1	Therapeutic UsesIBA 01/2022
1	CateninsIBA 01/2017
1	Chir 99021IBA 01/2017
1	Chymotrypsin FDA Link 07/2015
1	Ethanol (Ethyl Alcohol)IBA 07/2015
1	AntipyreticsIBA 07/2015
1	Proteasome Endopeptidase Complex (Proteasome)IBA 07/2015
1	Apoptosis Regulatory ProteinsIBA 07/2015
1	Ubiquitinated ProteinsIBA 07/2015

Therapy/Procedure

1	Immunotherapy 12/2022